{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,14]],"date-time":"2026-11-14T14:22:18Z","timestamp":1794666138804,"version":"4.9.1"},"reference-count":46,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"4","license":[{"start":{"date-parts":[[2025,12,10]],"date-time":"2025-12-10T00:00:00Z","timestamp":1765324800000},"content-version":"unspecified","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"funder":[{"name":"JST SPRING","award":["JPMJSP2138"],"award-info":[{"award-number":["JPMJSP2138"]}]}],"content-domain":{"domain":["lww.com","ovid.com"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2026,8]]},"abstract":"<jats:sec>\n                    <jats:title>Background:<\/jats:title>\n                    <jats:p>Tacrolimus-induced nephrotoxicity is a common adverse effect after liver transplantation. In this study, we aimed to develop a population pharmacokinetic\/pharmacodynamic (PK\/PD) model to evaluate the relationships among tacrolimus dose, instantaneous and cumulative exposure, and kidney injury.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods:<\/jats:title>\n                    <jats:p>\n                      Data from adult liver transplant recipients with a once-daily tacrolimus formulation were retrospectively analyzed. A sequential population PK\/PD modeling approach using nonlinear mixed-effects modeling was applied. Exposure metrics included trough concentrations, the area under the concentration\u2013time curve [area under the curve (AUC)] over a 24-hour (AUC\n                      <jats:sub>0\u201324h<\/jats:sub>\n                      ) period, and cumulative AUC (cAUC) over 1\u20136 months. Renal function was defined as the change in estimated glomerular filtration rate (eGFR). Demographics, biochemical parameters, and concomitant medications were evaluated as covariates.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results:<\/jats:title>\n                    <jats:p>Tacrolimus trough concentrations and eGFR measurements were obtained from a total of 44 patients for 3360 and 3504 measurements, respectively. Tacrolimus PK was best described by a one-compartment model with additive interindividual variability. Clearance was influenced by hematocrit (HCT) and postoperative days (PODs) within the first 14 days. Among exposure metrics, only cAUC over 3 months was significantly associated with renal function decline and provided the best model fit. The final PK\/PD model was a direct linear model, with baseline eGFR identified as a covariate on the slope, reflecting individual susceptibility to tacrolimus-associated renal changes.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions:<\/jats:title>\n                    <jats:p>Cumulative tacrolimus exposure over 3 months is a key determinant of nephrotoxicity and a valuable predictor for dose individualization. Our findings suggest that early PODs, HCT, and baseline renal function should be considered when optimizing tacrolimus therapy.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1097\/ftd.0000000000001418","type":"journal-article","created":{"date-parts":[[2025,12,10]],"date-time":"2025-12-10T15:00:54Z","timestamp":1765378854000},"page":"473-480","update-policy":"https:\/\/doi.org\/10.1097\/lww.0000000000001000","source":"Crossref","is-referenced-by-count":1,"title":["Population Pharmacokinetic\/Pharmacodynamic Model of the Impact of Cumulative Tacrolimus Exposure on Kidney Function After Liver Transplant"],"prefix":"10.1097","volume":"48","author":[{"given":"Ningjia","family":"Tang","sequence":"first","affiliation":[{"name":"Graduate School of Pharmaceutical Sciences, The University of Osaka, Osaka, Japan; and"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4012-4924","authenticated-orcid":false,"given":"Shinichirou","family":"Maeda","sequence":"additional","affiliation":[{"name":"Graduate School of Pharmaceutical Sciences, The University of Osaka, Osaka, Japan; and"},{"name":"Department of Pharmacy, The University of Osaka Hospital, Osaka, Japan."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Masahiro","family":"Okuda","sequence":"additional","affiliation":[{"name":"Graduate School of Pharmaceutical Sciences, The University of Osaka, Osaka, Japan; and"},{"name":"Department of Pharmacy, The University of Osaka Hospital, Osaka, Japan."}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"276","published-online":{"date-parts":[[2025,12,10]]},"reference":[{"key":"R1-20261114","doi-asserted-by":"crossref","first-page":"285","DOI":"10.1080\/14740338.2019.1599858","article-title":"An update on the safety of tacrolimus in kidney transplant recipients, with a focus on tacrolimus minimization","volume":"18","author":"Jouve","year":"2019","journal-title":"Expert Opin Drug Saf"},{"key":"R2-20261114","doi-asserted-by":"crossref","first-page":"484","DOI":"10.1097\/TP.0000000000003350","article-title":"Thirty years of tacrolimus in clinical practice","volume":"105","author":"Ong","year":"2021","journal-title":"Transplantation"},{"key":"R3-20261114","doi-asserted-by":"crossref","first-page":"261","DOI":"10.1097\/FTD.0000000000000640","article-title":"Therapeutic drug monitoring of tacrolimus-personalized therapy: second consensus report","volume":"41","author":"Brunet","year":"2019","journal-title":"Ther Drug Monit"},{"key":"R4-20261114","doi-asserted-by":"crossref","first-page":"623","DOI":"10.2165\/00003088-200443100-00001","article-title":"Clinical pharmacokinetics and pharmacodynamics of tacrolimus in solid organ transplantation","volume":"43","author":"Staatz","year":"2004","journal-title":"Clin Pharmacokinet"},{"key":"R5-20261114","doi-asserted-by":"crossref","first-page":"404","DOI":"10.2165\/00003088-199529060-00003","article-title":"Clinical pharmacokinetics of tacrolimus","volume":"29","author":"Venkataramanan","year":"1995","journal-title":"Clin Pharmacokinet"},{"key":"R7-20261114","doi-asserted-by":"crossref","first-page":"606","DOI":"10.1002\/j.1552-4604.1993.tb04712.x","article-title":"Pharmacokinetics of FK506 in liver transplant recipients after continuous intravenous infusion","volume":"33","author":"Jain","year":"1993","journal-title":"J Clin Pharmacol"},{"key":"R8-20261114","doi-asserted-by":"crossref","first-page":"1692","DOI":"10.1111\/bcp.13952","article-title":"Population pharmacokinetics of immediate- and prolonged-release tacrolimus formulations in liver, kidney and heart transplant recipients","volume":"85","author":"Lu","year":"2019","journal-title":"Br J Clin Pharmacol"},{"key":"R9-20261114","doi-asserted-by":"crossref","first-page":"1740","DOI":"10.1111\/bcp.13960","article-title":"Population pharmacokinetic model and Bayesian estimator for 2 tacrolimus formulations in adult liver transplant patients","volume":"85","author":"Riff","year":"2019","journal-title":"Br J Clin Pharmacol"},{"key":"R10-20261114","doi-asserted-by":"crossref","first-page":"331","DOI":"10.1016\/j.clpt.2006.06.008","article-title":"Population pharmacokinetic and pharmacogenomic analysis of tacrolimus in pediatric living-donor liver transplant recipients","volume":"80","author":"Fukudo","year":"2006","journal-title":"Clin Pharmacol Ther"},{"key":"R11-20261114","doi-asserted-by":"crossref","first-page":"54","DOI":"10.1097\/FTD.0b013e31829dcbcd","article-title":"Population pharmacokinetic analysis of tacrolimus early after pediatric liver transplantation","volume":"36","author":"Musuamba","year":"2014","journal-title":"Ther Drug Monit"},{"key":"R12-20261114","doi-asserted-by":"crossref","first-page":"281","DOI":"10.1038\/aps.2014.110","article-title":"A population pharmacokinetic study of tacrolimus in healthy Chinese volunteers and liver transplant patients","volume":"36","author":"Lu","year":"2015","journal-title":"Acta Pharmacol Sin"},{"key":"R13-20261114","doi-asserted-by":"crossref","first-page":"105237","DOI":"10.1016\/j.ejps.2020.105237","article-title":"Systematic external evaluation of published population pharmacokinetic models for tacrolimus in adult liver transplant recipients","volume":"145","author":"Cai","year":"2020","journal-title":"Eur J Pharm Sci"},{"key":"R14-20261114","doi-asserted-by":"crossref","first-page":"2793","DOI":"10.1111\/bcp.14110","article-title":"Toward a robust tool for pharmacokinetic-based personalization of treatment with tacrolimus in solid organ transplantation: a model-based meta-analysis approach","volume":"85","author":"Nanga","year":"2019","journal-title":"Br J Clin Pharmacol"},{"key":"R15-20261114","doi-asserted-by":"crossref","first-page":"1229","DOI":"10.1007\/s00228-024-03692-8","article-title":"External validation of population pharmacokinetic models of tacrolimus in Thai adult liver transplant recipients","volume":"80","author":"Komenkul","year":"2024","journal-title":"Eur J Clin Pharmacol"},{"key":"R16-20261114","doi-asserted-by":"crossref","first-page":"371","DOI":"10.1080\/00498254.2019.1631505","article-title":"Model extrapolation to a real-world dataset: evaluation of tacrolimus population pharmacokinetics and drug interaction in pediatric liver transplantation patients","volume":"50","author":"Wang","year":"2020","journal-title":"Xenobiotica"},{"key":"R17-20261114","doi-asserted-by":"crossref","first-page":"140","DOI":"10.1111\/aor.13551","article-title":"Tacrolimus: 20 years of use in adult kidney transplantation. What we should know about its nephrotoxicity","volume":"44","author":"Bentata","year":"2020","journal-title":"Artif Organs"},{"key":"R18-20261114","doi-asserted-by":"crossref","first-page":"334","DOI":"10.1093\/ndt\/10.3.334","article-title":"Nephrotoxicity of FK-506 in the rat. Studies on glomerular and tubular function, and on the relationship between efficacy and toxicity","volume":"10","author":"Nielsen","year":"1995","journal-title":"Nephrol Dial Transpl"},{"key":"R19-20261114","doi-asserted-by":"crossref","first-page":"2219","DOI":"10.1093\/clinchem\/39.11.2219","article-title":"FK506 (tacrolimus), a novel immunosuppressant in organ transplantation: clinical, biomedical, and analytical aspects","volume":"39","author":"Wallemacq","year":"1993","journal-title":"Clin Chem"},{"key":"R20-20261114","doi-asserted-by":"crossref","first-page":"60","DOI":"10.1097\/00000478-199301000-00007","article-title":"The histopathological changes associated with allograft rejection and drug toxicity in renal transplant recipients maintained on FK506. Clinical significance and comparison with cyclosporine","volume":"17","author":"Randhawa","year":"1993","journal-title":"Am J Surg Pathol"},{"key":"R21-20261114","doi-asserted-by":"crossref","first-page":"573","DOI":"10.1007\/s00228-017-2204-8","article-title":"High tacrolimus blood concentrations early after lung transplantation and the risk of kidney injury","volume":"73","author":"Sikma","year":"2017","journal-title":"Eur J Clin Pharmacol"},{"key":"R22-20261114","doi-asserted-by":"crossref","first-page":"168","DOI":"10.1016\/j.clpt.2005.04.008","article-title":"Pharmacodynamic analysis of tacrolimus and cyclosporine in living-donor liver transplant patients","volume":"78","author":"Fukudo","year":"2005","journal-title":"Clin Pharmacol Ther"},{"key":"R23-20261114","doi-asserted-by":"crossref","first-page":"e928858","DOI":"10.12659\/AOT.928858","article-title":"Association between trough level of tacrolimus and change in estimated glomerular filtration rate 1 year after living donor liver transplantation","volume":"26","author":"Muta","year":"2021","journal-title":"Ann Transpl"},{"key":"R24-20261114","doi-asserted-by":"crossref","first-page":"2114","DOI":"10.1111\/j.1600-6143.2007.01892.x","article-title":"Tacrolimus exposure and evolution of renal allograft histology in the first year after transplantation","volume":"7","author":"Naesens","year":"2007","journal-title":"Am J Transpl"},{"key":"R25-20261114","doi-asserted-by":"crossref","first-page":"434","DOI":"10.1016\/j.clpt.2003.12.009","article-title":"Clinical efficacy and toxicity profile of tacrolimus and mycophenolic acid in relation to combined long-term pharmacokinetics in de novo renal allograft recipients","volume":"75","author":"Kuypers","year":"2004","journal-title":"Clin Pharmacol Ther"},{"key":"R26-20261114","doi-asserted-by":"crossref","first-page":"17","DOI":"10.1111\/j.1365-2710.2006.00697.x","article-title":"Relationships of tacrolimus pharmacokinetic measures and adverse outcomes in stable adult liver transplant recipients","volume":"31","author":"Dansirikul","year":"2006","journal-title":"J Clin Pharm Ther"},{"key":"R27-20261114","doi-asserted-by":"crossref","first-page":"2539","DOI":"10.1097\/TP.0000000000002760","article-title":"Area under trough concentrations of tacrolimus as a predictor of progressive renal impairment after liver transplantation","volume":"103","author":"Rodr\u00edguez-Per\u00e1lvarez","year":"2019","journal-title":"Transplantation"},{"key":"R28-20261114","doi-asserted-by":"crossref","first-page":"993","DOI":"10.1007\/s40262-015-0282-2","article-title":"Clinical pharmacokinetics of once-daily tacrolimus in solid-organ transplant patients","volume":"54","author":"Staatz","year":"2015","journal-title":"Clin Pharmacokinet"},{"key":"R29-20261114","doi-asserted-by":"crossref","first-page":"1013","DOI":"10.1097\/TP.0b013e31826bc400","article-title":"Comparison of pharmacokinetics and pharmacogenetics of once- and twice-daily tacrolimus in the early stage after renal transplantation","volume":"94","author":"Niioka","year":"2012","journal-title":"Transplantation"},{"key":"R30-20261114","doi-asserted-by":"crossref","first-page":"479","DOI":"10.1007\/s002280100331","article-title":"Population pharmacokinetics of tacrolimus in adult recipients receiving living-donor liver transplantation","volume":"57","author":"Fukatsu","year":"2001","journal-title":"Eur J Clin Pharmacol"},{"key":"R31-20261114","doi-asserted-by":"crossref","first-page":"1161","DOI":"10.2165\/00003088-200342130-00006","article-title":"Forecasting of blood tacrolimus concentrations based on the Bayesian method in adult patients receiving living-donor liver transplantation","volume":"42","author":"Fukudo","year":"2003","journal-title":"Clin Pharmacokinet"},{"key":"R32-20261114","doi-asserted-by":"crossref","first-page":"1385","DOI":"10.1002\/cpdd.971","article-title":"Effects of postoperative day and NR1I2 on tacrolimus clearance in Chinese liver transplant recipients-a population model approach","volume":"10","author":"Lu","year":"2021","journal-title":"Clin Pharmacol Drug Dev"},{"key":"R33-20261114","doi-asserted-by":"crossref","first-page":"2119","DOI":"10.2147\/TCRM.S184376","article-title":"CYP3A5 genotype-based model to predict tacrolimus dosage in the early postoperative period after living donor liver transplantation","volume":"14","author":"Ji","year":"2018","journal-title":"Ther Clin Risk Manag"},{"key":"R34-20261114","doi-asserted-by":"crossref","first-page":"412","DOI":"10.1097\/FTD.0b013e318178e31b","article-title":"Pharmacokinetic-pharmacodynamic assessment of tacrolimus in liver-transplant recipients during the early post-transplantation period","volume":"30","author":"Blanchet","year":"2008","journal-title":"Ther Drug Monit"},{"key":"R35-20261114","doi-asserted-by":"crossref","first-page":"840","DOI":"10.3109\/00498254.2015.1021733","article-title":"Effects of CYP3A5 genotypes, ABCB1 C3435T and G2677T\/A polymorphism on pharmacokinetics of Tacrolimus in Chinese adult liver transplant patients","volume":"45","author":"Zhu","year":"2015","journal-title":"Xenobiotica"},{"key":"R36-20261114","doi-asserted-by":"crossref","first-page":"126","DOI":"10.1097\/FTD.0b013e31824a67eb","article-title":"The impact of sulfonylureas on tacrolimus apparent clearance revealed by a population pharmacokinetics analysis in Chinese adult liver-transplant patients","volume":"34","author":"Zhang","year":"2012","journal-title":"Ther Drug Monit"},{"key":"R37-20261114","doi-asserted-by":"crossref","first-page":"130","DOI":"10.1053\/jlts.2003.50023","article-title":"Toward better outcomes with tacrolimus therapy: population pharmacokinetics and individualized dosage prediction in adult liver transplantation","volume":"9","author":"Staatz","year":"2003","journal-title":"Liver Transpl"},{"key":"R38-20261114","doi-asserted-by":"crossref","first-page":"76","DOI":"10.1002\/bdd.2311","article-title":"Population pharmacokinetics of tacrolimus in Chinese adult liver transplant patients","volume":"43","author":"Teng","year":"2022","journal-title":"Biopharm Drug Dispos"},{"key":"R39-20261114","doi-asserted-by":"crossref","first-page":"409","DOI":"10.1007\/s00228-005-0933-6","article-title":"Population pharmacokinetics of tacrolimus in full liver transplant patients: modelling of the post-operative clearance","volume":"61","author":"Antignac","year":"2005","journal-title":"Eur J Clin Pharmacol"},{"key":"R40-20261114","doi-asserted-by":"crossref","first-page":"e542","DOI":"10.1002\/ctm2.542","article-title":"The CYP3A5 genotypes of both liver transplant recipients and donors influence the time-dependent recovery of tacrolimus clearance during the early stage following transplantation","volume":"11","author":"Huang","year":"2021","journal-title":"Clin Transl Med"},{"key":"R41-20261114","doi-asserted-by":"crossref","first-page":"413","DOI":"10.1097\/FPC.0b013e3282f9ac01","article-title":"Impact of MDR1 and CYP3A5 on the oral clearance of tacrolimus and tacrolimus-related renal dysfunction in adult living-donor liver transplant patients","volume":"18","author":"Fukudo","year":"2008","journal-title":"Pharmacogenet Genomics"},{"key":"R42-20261114","doi-asserted-by":"crossref","first-page":"963","DOI":"10.1002\/psp4.12966","article-title":"Population PK\/PD model of tacrolimus for exploring the relationship between accumulated exposure and quantitative scores in myasthenia gravis patients","volume":"12","author":"Chen","year":"2023","journal-title":"CPT Pharmacometrics Syst Pharmacol"},{"key":"R43-20261114","doi-asserted-by":"crossref","first-page":"111461","DOI":"10.1016\/j.intimp.2023.111461","article-title":"Adequate cumulative exposure to tacrolimus and low tacrolimus variability decrease the incidence of biliary complications after liver transplantation","volume":"128","author":"Pan","year":"2024","journal-title":"Int Immunopharmacol"},{"key":"R44-20261114","doi-asserted-by":"crossref","first-page":"1671","DOI":"10.1111\/ajt.17021","article-title":"Cumulative exposure to tacrolimus and incidence of cancer after liver transplantation","volume":"22","author":"Rodr\u00edguez-Per\u00e1lvarez","year":"2022","journal-title":"Am J Transpl"},{"key":"R45-20261114","doi-asserted-by":"crossref","first-page":"1294","DOI":"10.1111\/tri.12435","article-title":"A randomized cross-over comparison of short-term exposure of once-daily extended release tacrolimus and twice-daily tacrolimus on renal function in healthy volunteers","volume":"27","author":"Zaltzman","year":"2014","journal-title":"Transpl Int"},{"key":"R46-20261114","doi-asserted-by":"crossref","first-page":"467","DOI":"10.1016\/j.healun.2021.02.017","article-title":"Once daily tacrolimus conversion in lung transplantation: a prospective study on safety and medication adherence","volume":"40","author":"Godinas","year":"2021","journal-title":"J Heart Lung Transpl"},{"key":"R47-20261114","doi-asserted-by":"crossref","first-page":"10384","DOI":"10.3389\/ti.2022.10384","article-title":"Renal function, adherence and quality of life improvement after conversion from immediate to prolonged-release tacrolimus in liver transplantation: Prospective Ten-Year Follow-Up Study","volume":"35","author":"Toti","year":"2022","journal-title":"Transpl Int"}],"container-title":["Therapeutic Drug Monitoring"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.ovid.com\/10.1097\/FTD.0000000000001418","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,11,14]],"date-time":"2026-11-14T14:00:32Z","timestamp":1794664832000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.ovid.com\/10.1097\/FTD.0000000000001418"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,12,10]]},"references-count":46,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2026]]}},"URL":"https:\/\/doi.org\/10.1097\/ftd.0000000000001418","relation":{},"ISSN":["0163-4356","1536-3694"],"issn-type":[{"value":"0163-4356","type":"print"},{"value":"1536-3694","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,12,10]]},"assertion":[{"value":"2025-09-18","name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2025-10-22","name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}}]}}